Physician profile
Michael Comer
NPI 1699155119
$1,666.22
in general payments reported to CMS, 2019-2025
28 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $20.12 · 2022: $205 · 2023: $254 · 2024: $341 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $247.65 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $157.69 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $146.40 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $126.64 | 2019 | |
| Abbvie INC. | $114.87 | 2022-2025 | |
| Glaxosmithkline, LLC. | $87.07 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $78.50 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $76.83 | 2019 | |
| Pfizer INC. | $70.96 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.30 | 2019-2025 | Jardiance |
| Stryker Corporation | $51.39 | 2025 | Clottriever Bold Catheter, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Dynavax Technologies Corporation | $50.91 | 2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $49.90 | 2019 | |
| Shire North American Group INC | $48.11 | 2019 | |
| Amgen INC. | $46.13 | 2019-2025 | Krystexxa, Otezla, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.34 | 2019-2025 | Xifaxan |
| Inari Medical, INC. | $30.51 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $27.27 | 2019 | |
| Lilly USA, LLC | $25.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $22.16 | 2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $20.12 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.27 | 2019 | |
| Corcept Therapeutics | $17.39 | 2024 | Korlym |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.18 | 2022 | |
| Merck Sharp & Dohme LLC | $14.94 | 2019 | |
| Daiichi Sankyo INC. | $13.56 | 2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $11.46 | 2019 | |
| Amarin Pharma, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Comer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.